Website
News25/Ratings11
News · 26 weeks36-20%
2025-10-262026-04-19
Mix1190d
- Earnings3(27%)
- SEC Filings3(27%)
- Insider2(18%)
- Leadership2(18%)
- Other1(9%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Presti Mariyamma Varghese3 - OptimizeRx Corp (0001448431) (Issuer)
- PRMyomo Appoints William J Febbo to its Board of DirectorsMyomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William "Will" Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant ca
- PROptimizeRx Appoints Mary Varghese Presti to Board of DirectorsWALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Mary Varghese Presti to its Board of Directors. The appointment of Varghese Presti as an independent director is in furtherance of the Company's ongoing process to refresh and expand its Board of Directors. Varghese Presti brings more than 25 years of experience at the intersection of healthcare, life sciences, and technology, with a track record of building and scaling platforms that translate innovation into real-world
- SECOptimizeRx Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - OptimizeRx Corp (0001448431) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by OptimizeRx CorporationSCHEDULE 13G/A - OptimizeRx Corp (0001448431) (Subject)
- SECSEC Form 10-K filed by OptimizeRx Corporation10-K - OptimizeRx Corp (0001448431) (Filer)
- PRUPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today
- SECOptimizeRx Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - OptimizeRx Corp (0001448431) (Filer)
- PROptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today
- INSIDERChief Legal & Admin Officer Odence-Ford Marion converted options into 4,000 shares and covered exercise/tax liability with 1,386 shares, increasing direct ownership by 3% to 91,936 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- PROptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ETWALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Thursday, March 5, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific T
- PROptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare MarketingWALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data and technology company. This integration maps OptimizeRx Micro-Neighborhood® audiences to Experian's identity graph, enabling seamless onboarding and curated audience activation, delivering a transparent, reliable methodology for life sciences brands and healthcare marketing agencies to reach and measure consumer audiences at scale. Addressing Fragmentation that
- INSIDERAmendment: Chief Executive Officer Silvestro Stephen L covered exercise/tax liability with 3,361 shares, decreasing direct ownership by 2% to 190,507 units (SEC Form 4)4/A - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Commercial Officer Greco Theresa covered exercise/tax liability with 1,420 shares, decreasing direct ownership by 2% to 72,868 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Executive Officer Silvestro Stephen L covered exercise/tax liability with 3,361 shares, decreasing direct ownership by 2% to 190,507 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Legal & Admin Officer Odence-Ford Marion covered exercise/tax liability with 4,051 shares, decreasing direct ownership by 4% to 89,322 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Product & Tech Officer Besch Doug covered exercise/tax liability with 4,079 shares, decreasing direct ownership by 6% to 66,876 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Finance & Strat Officer Stelmakh Edward covered exercise/tax liability with 3,658 shares, decreasing direct ownership by 3% to 123,172 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERAmendment: Chief Finance & Strat Officer Stelmakh Edward converted options into 5,237 shares and covered exercise/tax liability with 1,388 shares, increasing direct ownership by 3% to 126,830 units (SEC Form 4)4/A - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Finance & Strat Officer Stelmakh Edward converted options into 5,237 shares and sold $18,752 worth of shares (1,388 units at $13.51), increasing direct ownership by 3% to 126,830 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Executive Officer Silvestro Stephen L converted options into 6,546 shares and covered exercise/tax liability with 1,594 shares, increasing direct ownership by 3% to 193,868 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Legal & Admin Officer Odence-Ford Marion converted options into 3,928 shares and covered exercise/tax liability with 1,153 shares, increasing direct ownership by 3% to 93,373 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Merrell Brendan W. covered exercise/tax liability with 289 shares, decreasing direct ownership by 1% to 26,207 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Business Officer D'Silva Andrew J. covered exercise/tax liability with 703 shares, decreasing direct ownership by 2% to 44,735 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)
- INSIDERChief Product & Tech Officer Besch Doug converted options into 1,964 shares and covered exercise/tax liability with 581 shares, increasing direct ownership by 2% to 70,955 units (SEC Form 4)4 - OptimizeRx Corp (0001448431) (Issuer)